Literature DB >> 16782776

Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.

S S O'Sullivan, E M Cronin, B J Sweeney, J F Bourke, J Fitzgibbon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782776      PMCID: PMC2077407          DOI: 10.1136/jnnp.2006.094813

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Authors:  Antonie Giaever Beiske; Kjell-Morten Myhr
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 2.  Multiple sclerosis: side effects of interferon beta therapy and their management.

Authors:  E U Walther; R Hohlfeld
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

Review 3.  Panniculitis. Part II. Mostly lobular panniculitis.

Authors:  L Requena; E Sánchez Yus
Journal:  J Am Acad Dermatol       Date:  2001-09       Impact factor: 11.527

4.  Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.

Authors:  Mathias Buttmann; Matthias Goebeler; Atiye Toksoy; Sybille Schmid; Wolfgang Graf; Friederike Berberich-Siebelt; Peter Rieckmann
Journal:  J Neuroimmunol       Date:  2005-08-26       Impact factor: 3.478

5.  Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.

Authors:  Lucie Heinzerling; Reinhard Dummer; Günter Burg; Peter Schmid-Grendelmeier
Journal:  Eur J Dermatol       Date:  2002 Mar-Apr       Impact factor: 3.328

  5 in total
  1 in total

1.  Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.

Authors:  Abirami Pararajasingam; Rachel E Bradley; Jennifer Evans; Ashima Lowe; Richard Goodwin; Stephen Jolles
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.418

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.